Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV ‐suppressed individuals: 48 weeks and beyond
HIV Medicine · 2026
DOI: 10.1111/hiv.70247 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV Medicine, 2026. Verfasst von Tommy Hing-Cheung Tang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Queen Elizabeth Hospital, Hong Kong Special Administrative Region, China. Hauptthemen laut MEDLINE: HIV Infections, Lamivudine, Heterocyclic Compounds, 3-Ring, Anti-HIV Agents. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Methods
We retrospectively identified virally suppressed PWH who switched from standard ART to DTG + 3TC at Queen Elizabeth Hospital, Hong Kong, China. They were grouped by age (PWH =50 years: PWH > =50). Their demographics, clinical and laboratory data before and 48 weeks after switch were compared.
Results
Subjects included 352 PWH (84.7% male, 48.7% PWH > =50, median ART duration 8.3 years). At 48 weeks post‐switch, 96.0% maintained DTG + 3TC with two (1.1%) in the PWH < 50 and three (1.7%) in the PWH > =50 experienced virological failure. There was no significant difference in virological failure (hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.11, 3.77, p = 0.613) or 2DR discontinuation (HR 0.95, 95% CI 0.33, 2.71, p = 0.926; restricted mean survival time (RMST) difference 0.23 weeks, 95% CI −0.64, 1.10, p = 0.600) between the groups. PWH > =50 exhibited a greater total cholesterol reduction than PWH < 50 post‐switch (median change −4.8% (IQR −17.5%, 5.9%) versus 0.4% (IQR −8.1%, 8.2%), p = 0.005). Two sensitivity analyses excluding lipid‐lowering drug users and restricting to INSTI‐based ART users before switch yielded negative results.
Conclusions
In this Chinese‐majority cohort, switching from standard ART to DTG + 3TC was well tolerated at 48 weeks by both younger and older PWH. Despite more comorbidities in PWH > =50, their changes in laboratory outcomes post‐switch were comparable to PWH < 50.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Queen Elizabeth Hospital, Hong Kong Special Administrative Region, China.
- Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA.
- Yale Center for Brain and Mind Health, Yale University School of Medicine, New Haven, Connecticut, USA.
- Department of Medicine and Geriatrics, Kwong Wah Hospital, Hong Kong Special Administrative Region, China.
ORCID-Profile: Tommy Hing-Cheung Tang, Ruby Tsz-Shan Kwong, Phillip Chan, Man-Yee Chu, Wai-Shing Leung
Zitieren
APA
Tang, T. H., Kwong, R. T., Chan, P., Lam, K. W., Chan, H. S., Chu, M. Y., Lam, W., Wu, T. C., Leung, W. S., Yung, S. K., Ting, W. M., Choy, A. K., Tung, J. L., Fong, J. K., Yeung, D. K., & Lee, M. P. (2026). Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV ‐suppressed individuals: 48 weeks and beyond. HIV Medicine. https://doi.org/10.1111/hiv.70247
Vancouver
Tang TH, Kwong RT, Chan P, Lam KW, Chan HS, Chu MY, et al. Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV ‐suppressed individuals: 48 weeks and beyond. HIV Medicine. 2026. doi:10.1111/hiv.70247
BibTeX
@article{Tang2026,
author = {Tang, Tommy Hing-Cheung and Kwong, Ruby Tsz-Shan and Chan, Phillip and Lam, Kwok-Wai and Chan, Helen Shuk-Ying and Chu, Man-Yee and Lam, Wilson and Wu, Tak-Chiu and Leung, Wai-Shing and Yung, Sai-Kwong and Ting, Wan-Man and Choy, Annabel Kai-Tung and Tung, Joe Lok-Fung and Fong, Jason Ka-Wah and Yeung, Daniel Kai-Yeung and Lee, Man-Po},
title = {Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV ‐suppressed individuals: 48 weeks and beyond},
journal = {HIV Medicine},
year = {2026},
doi = {10.1111/hiv.70247}
}
EUVIMED